Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Change in Accured Expenses (2024 - 2025)

Indivior Pharmaceuticals has reported Change in Accured Expenses over the past 2 years, most recently at -$8.0 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$8.0 million for Q4 2025, up 87.3% from a year ago — trailing twelve months through Dec 2025 was $41.0 million (up 412.5% YoY), and the annual figure for FY2025 was $41.0 million, up 412.5%.
  • Change in Accured Expenses for Q4 2025 was -$8.0 million at Indivior Pharmaceuticals, up from -$82.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for INDV hit a ceiling of $81.0 million in Q1 2025 and a floor of -$82.0 million in Q3 2025.